Equities Analysts Issue Forecasts for JANX FY2026 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Janux Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($4.43) for the year. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share.

Other analysts have also issued research reports about the company. Scotiabank reduced their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Wedbush reissued an “outperform” rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Buy” and an average price target of $95.25.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX opened at $26.24 on Tuesday. The firm’s 50 day moving average price is $26.98 and its 200-day moving average price is $37.44. Janux Therapeutics has a 52-week low of $22.48 and a 52-week high of $71.71. The company has a market cap of $1.55 billion, a PE ratio of -22.43 and a beta of 2.96.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its stake in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares during the period. Avanza Fonder AB boosted its holdings in shares of Janux Therapeutics by 17.0% during the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company’s stock valued at $86,000 after purchasing an additional 444 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Janux Therapeutics by 3.0% in the first quarter. New York State Common Retirement Fund now owns 16,435 shares of the company’s stock worth $444,000 after purchasing an additional 471 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after buying an additional 599 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its holdings in Janux Therapeutics by 20.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company’s stock valued at $109,000 after buying an additional 686 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Andrew Hollman Meyer sold 3,333 shares of the firm’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. This trade represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 8.10% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.